Previous Close | 5.00 |
Open | 5.11 |
Bid | 4.95 x 300 |
Ask | 5.03 x 500 |
Day's Range | 4.90 - 5.39 |
52 Week Range | 0.36 - 5.89 |
Volume | |
Avg. Volume | 3,120,918 |
Market Cap | 243.742M |
Beta (5Y Monthly) | 1.35 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.34 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 7.75 |
Strategic Advances Amidst Financial Prudence
Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced financial results for the quarter and full-year ended December 31, 2023, and highlighted recent business achievements.
Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical need, today announced that it will present preclinical proof-of-concept data for its differentiated HER3-targeting antibody-drug conjugate (ADC) program in a poster session at the American Association for Cancer Research (AACR) Annual Meeting 2024, being held April 5-10 in San